Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study
Bildiriler > Özet Bildiri · 2019
Yazarlar: ANIL TOMBAK, PEPEDİL FUNDA, SALİH SERTAÇ DURUSOY, EMEL GÜRKAN, EMİN KAYA, ELİF GÜLSÜM ÜMİT, İRFAN YAVAŞOĞLU, ÖZGÜR MEHTAP, BURAK DEVECİ, MEHMET ALİ ÖZCAN, HATİCE TERZİ, MÜFİDE OKAY, NİLGÜN SAYINALP, MEHMET YILMAZ, VAHAP OKAN, ALPEREN İKİZLİ, ÖMER ÖZCAN, GÜVEN ÇETİN, SİNAN DEMİRCİOĞLU, İSMET AYDOĞDU, Güray SAYDAM, EREN DAVULCU, GÜL İLHAN, MEHMET ALİ UÇAR, GÜLSÜM ÖZET, SEVAL AKPINAR, BURHAN TURGUT, İLHAMİ BERBER, ERDAL KURTOĞLU, MEHMET SÖNMEZ, DERYA SELİM BATUR, RAHŞAN YILDIRIM, VİLDAN ÖZKOCAMAN, AHMET KÜRŞAT GÜNEŞ, BİRSEN SAHİP, ŞEHMUS ERTOP, OLGA MELTEM AKAY, ABDULKADİR BAŞTÜRK, MEHMET HİLMİ DOĞU, AYDAN AKDENİZ, ALİ ÜNAL, AHMET SEYHANLI, AHMET BURHAN FERHANOĞLU
Blood, Amerika Birleşik Devletleri, Uluslararası, Poster, Özet Bildiri, 2019-2019, Wos, cilt 134, ss 5476-5476
DOI: 10.1182/blood-2019-126402
Özet
Introduction: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia seen in adults. Ibrutinib is an orally administered irreversible inhibitor of Bruton tyrosine kinase. Ibrutinib monotherapy has been found effective in many CLL studies. This study aimed at investigating the real world experiences of patients with CLL who have been treated with ibrutinib in Turkey. Materials and Methods: This retrospective multicenter study included 136 patients (91 male) from 33 sites who received at least 1 cycle of ibrutinib since February 2013. Results: The median age was 64. The median follow up time from the initial diagnosis was 69 months (range: 9-296). An average of 2 treatment protocols had been given (range: 0-7) before ibrutinib and the median time elapsed from the last treatment to the date of ibrutinib administration was 6 months (range: 0-120 months). Before ibrutinib, 51.5% of the patients had a comorbidity, 21.3% a bulky disease and 52.2% a B symptom. Of the patients, 87.9% had ECOG <3, 23.8% RAI stage Conclusion: These real world experiences have shown that the ibrutinib monotherapy with its tolerable side effects is an effective treatment option regardless of the poor prognostic gene mutations in patients with CLL Disclosures No relevant conflicts of interest to declare.